ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Details How Year 2000 Goals Can Be Reached Bypass Budget Spells Out How Much It Will Cost

June 8, 1984

In Brief: McDonnell Foundation Selects Five For Awards; James Benson Is Named Interim FDA Head

November 24, 1989

Biomedical Panel To Hear Public At Sept. Meeting

July 11, 1975

As Leadership Changes Continue, Fontaine, Leach Get New Posts

January 17, 2014

Susan Weiner Named to HHS Panel

January 17, 2003

In Brief: New York Legislature Votes $240 Mil. Bond Issue For Roswell Park Construction; Kripke Honored

April 25, 1992